Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Westervelt

Showing results (281-290 of 359) with videos related to

Pageof 36
Sort By:
Transplantation and Cellular Therapy|August 19, 2023
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell TransplantationZiheng Xu, Jaebok Choi, Matthew Cooper, et al.
Frontiers in Aging Neuroscience|May 6, 2014
Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD StudyJane S Paulsen, Jeffrey D Long, Hans J Johnson, et al.
Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with <i>FLT3</i>-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Blood|November 22, 2024
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantationRamzi Abboud, Mark A Schroeder, Michael P Rettig, et al.
Bone Marrow Transplantation|July 19, 2016
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantationJ Magenau, P Westervelt, S Khaled, et al.
Leukemia & Lymphoma|January 20, 2021
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromesEric Huselton, Michael P Rettig, Theresa Fletcher, et al.
Cell|April 2, 2019
Steroid Hormone Function Controls Non-competitive Plasmodium Development in AnophelesKristine Werling, W Robert Shaw, Maurice A Itoe, et al.
Blood|March 16, 2017
Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graftMark A Schroeder, Michael P Rettig, Sandra Lopez, et al.
Frontiers in Neurology|March 18, 2022
Relaxation-Compensated Chemical Exchange Saturation Transfer MRI in the Brain at 7T: Application in Relapsing-Remitting Multiple SclerosisKristin P O'Grady, Sanjana Satish, Quinn R Owen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic SyndromeRyotaro Nakamura, Wael Saber, Michael J Martens, et al.
Pageof 36

Showing results (281-290 of 359) with videos related to

Sort By:
Pageof 36
Transplantation and Cellular Therapy|August 19, 2023
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell TransplantationZiheng Xu, Jaebok Choi, Matthew Cooper, et al.
Frontiers in Aging Neuroscience|May 6, 2014
Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD StudyJane S Paulsen, Jeffrey D Long, Hans J Johnson, et al.
Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with <i>FLT3</i>-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Blood|November 22, 2024
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantationRamzi Abboud, Mark A Schroeder, Michael P Rettig, et al.
Bone Marrow Transplantation|July 19, 2016
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantationJ Magenau, P Westervelt, S Khaled, et al.
Leukemia & Lymphoma|January 20, 2021
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromesEric Huselton, Michael P Rettig, Theresa Fletcher, et al.
Cell|April 2, 2019
Steroid Hormone Function Controls Non-competitive Plasmodium Development in AnophelesKristine Werling, W Robert Shaw, Maurice A Itoe, et al.
Blood|March 16, 2017
Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graftMark A Schroeder, Michael P Rettig, Sandra Lopez, et al.
Frontiers in Neurology|March 18, 2022
Relaxation-Compensated Chemical Exchange Saturation Transfer MRI in the Brain at 7T: Application in Relapsing-Remitting Multiple SclerosisKristin P O'Grady, Sanjana Satish, Quinn R Owen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2021
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic SyndromeRyotaro Nakamura, Wael Saber, Michael J Martens, et al.
Pageof 36